New advances in nanotechnology-based diagnosis and therapeutics for breast cancer: An assessment of active-targeting inorganic nanoplatforms

Priscila Falagan-Lotsch, Elissa M. Grzincic, Catherine J. Murphy

Research output: Contribution to journalReview article

Abstract

Breast cancer is a major cause of suffering and mortality among women. Limitations in the current diagnostic methods and treatment approaches have led to new strategies to positively impact the survival rates and quality of life of breast cancer patients. Nanotechnology offers a real possibility of mitigating breast cancer mortality by early-stage cancer detection and more precise diagnosis as well as more effective treatments with minimal side effects. The current nanoplatforms approved for breast cancer therapeutics are based on passive tumor targeting using organic nanoparticles and have not provided the expected significant improvements in the clinic. In this review, we present the emerging approaches in breast cancer nanomedicine based on active targeting using versatile inorganic nanoplatforms with biomedical relevance, such as gold, silica, and iron oxide nanoparticles, as well as their efficacy in breast cancer imaging, drug and gene delivery, thermal therapy, combinational therapy, and theranostics in preclinical studies. The main challenges for clinical translation and perspectives are discussed.

Original languageEnglish (US)
Pages (from-to)135-152
Number of pages18
JournalBioconjugate Chemistry
Volume28
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Nanotechnology
Breast Neoplasms
Nanoparticles
Medical nanotechnology
Iron oxides
Silicon Dioxide
Gold
Tumors
Genes
Silica
Imaging techniques
Therapeutics
Pharmaceutical Preparations
Nanomedicine
Mortality
Early Detection of Cancer
Psychological Stress
Survival Rate
Hot Temperature
Quality of Life

ASJC Scopus subject areas

  • Biotechnology
  • Bioengineering
  • Biomedical Engineering
  • Pharmacology
  • Pharmaceutical Science
  • Organic Chemistry

Cite this

New advances in nanotechnology-based diagnosis and therapeutics for breast cancer : An assessment of active-targeting inorganic nanoplatforms. / Falagan-Lotsch, Priscila; Grzincic, Elissa M.; Murphy, Catherine J.

In: Bioconjugate Chemistry, Vol. 28, No. 1, 01.01.2017, p. 135-152.

Research output: Contribution to journalReview article

@article{da91c78948864e72a15adf014a8e08a6,
title = "New advances in nanotechnology-based diagnosis and therapeutics for breast cancer: An assessment of active-targeting inorganic nanoplatforms",
abstract = "Breast cancer is a major cause of suffering and mortality among women. Limitations in the current diagnostic methods and treatment approaches have led to new strategies to positively impact the survival rates and quality of life of breast cancer patients. Nanotechnology offers a real possibility of mitigating breast cancer mortality by early-stage cancer detection and more precise diagnosis as well as more effective treatments with minimal side effects. The current nanoplatforms approved for breast cancer therapeutics are based on passive tumor targeting using organic nanoparticles and have not provided the expected significant improvements in the clinic. In this review, we present the emerging approaches in breast cancer nanomedicine based on active targeting using versatile inorganic nanoplatforms with biomedical relevance, such as gold, silica, and iron oxide nanoparticles, as well as their efficacy in breast cancer imaging, drug and gene delivery, thermal therapy, combinational therapy, and theranostics in preclinical studies. The main challenges for clinical translation and perspectives are discussed.",
author = "Priscila Falagan-Lotsch and Grzincic, {Elissa M.} and Murphy, {Catherine J.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1021/acs.bioconjchem.6b00591",
language = "English (US)",
volume = "28",
pages = "135--152",
journal = "Bioconjugate Chemistry",
issn = "1043-1802",
publisher = "American Chemical Society",
number = "1",

}

TY - JOUR

T1 - New advances in nanotechnology-based diagnosis and therapeutics for breast cancer

T2 - An assessment of active-targeting inorganic nanoplatforms

AU - Falagan-Lotsch, Priscila

AU - Grzincic, Elissa M.

AU - Murphy, Catherine J.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Breast cancer is a major cause of suffering and mortality among women. Limitations in the current diagnostic methods and treatment approaches have led to new strategies to positively impact the survival rates and quality of life of breast cancer patients. Nanotechnology offers a real possibility of mitigating breast cancer mortality by early-stage cancer detection and more precise diagnosis as well as more effective treatments with minimal side effects. The current nanoplatforms approved for breast cancer therapeutics are based on passive tumor targeting using organic nanoparticles and have not provided the expected significant improvements in the clinic. In this review, we present the emerging approaches in breast cancer nanomedicine based on active targeting using versatile inorganic nanoplatforms with biomedical relevance, such as gold, silica, and iron oxide nanoparticles, as well as their efficacy in breast cancer imaging, drug and gene delivery, thermal therapy, combinational therapy, and theranostics in preclinical studies. The main challenges for clinical translation and perspectives are discussed.

AB - Breast cancer is a major cause of suffering and mortality among women. Limitations in the current diagnostic methods and treatment approaches have led to new strategies to positively impact the survival rates and quality of life of breast cancer patients. Nanotechnology offers a real possibility of mitigating breast cancer mortality by early-stage cancer detection and more precise diagnosis as well as more effective treatments with minimal side effects. The current nanoplatforms approved for breast cancer therapeutics are based on passive tumor targeting using organic nanoparticles and have not provided the expected significant improvements in the clinic. In this review, we present the emerging approaches in breast cancer nanomedicine based on active targeting using versatile inorganic nanoplatforms with biomedical relevance, such as gold, silica, and iron oxide nanoparticles, as well as their efficacy in breast cancer imaging, drug and gene delivery, thermal therapy, combinational therapy, and theranostics in preclinical studies. The main challenges for clinical translation and perspectives are discussed.

UR - http://www.scopus.com/inward/record.url?scp=85021860224&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021860224&partnerID=8YFLogxK

U2 - 10.1021/acs.bioconjchem.6b00591

DO - 10.1021/acs.bioconjchem.6b00591

M3 - Review article

C2 - 27973767

AN - SCOPUS:85021860224

VL - 28

SP - 135

EP - 152

JO - Bioconjugate Chemistry

JF - Bioconjugate Chemistry

SN - 1043-1802

IS - 1

ER -